Urolithin A (often shortened to “UA” in these studies) is a compound our gut bacteria can make when eating ellagitannin‑rich foods like pomegranate seeds or walnuts.
Because this compound is much smaller and more easily absorbed than the original plant polyphenols, scientists are investigating whether UA can influence cell health to help us live longer and healthier.
No human research has proven that urolithin A can treat, cure, or prevent cancer. Today, urolithin a is only sold as a dietary supplement. We want to explain what scientists have discovered so far and where the research still needs to go.
How Might Urolithin A Interact with Cancer Cells?
Research groups have repeatedly seen urolithin A influence key “hallmarks of cancer” in Petri dishes and rodents. They found urolithin A might affect cancer in six distinct pathways:
In multiple cancer‑cell experiments, urolithin A applied at micromolar doses slows the cell‑division clock, stalling cells at the S or G₂/M checkpoints.
This essentially forces the fast-growing cancer cells to pause before they can finish duplicating themselves. This is important because the tumor can't grow as quickly when cells can't keep dividing [1, 2].
Keeping Cells That Refuse to Die in Check
Healthy bodies have a “self‑destruct” button that removes damaged cells. This button is called apoptosis (programmed cell death) — the problem is that cancer cells often break or ignore that button.
In these studies, researchers found that urolithin A helps switch the apoptosis button back on by activating caspase-3/7 and other "executioner" enzymes," so the bad cells pop like soap bubbles instead of hanging around and wreaking havoc on healthy tissue [1,2].
Supporting Healthy Mitochondria
Urolithin A has been researched for its role in supporting mitophagy — the body's process of removing old, worn-out mitochondria and replacing them with new ones.
By keeping the cell's powerhouse running smoothly, tumor cells might have difficulty thriving in a smooth-running system [1, 2].
Supporting Healthy Inflammation
Tumors like inflamed environments. The lab and rodent studies show that urolithin A reduced pro-inflammatory messengers like IL‑6, IL‑1β and the master switch NF‑κB [1,2].
Because chronic inflammation can act like fertilizer for tumors, dialing it down may indirectly stop cancer growth.
May Inhibit Cancer from Spreading to New Places (Metastasis)
For cancer to travel beyond where it started, cells must change shape and crawl away. In these early studies, urolithin A was able to block the “shape‑shifter” instructions — epithelial‑to‑mesenchymal transition (EMT), if you want to get technical — so the cells stay put instead of spreading to new areas, which is what makes it lethal most of the time [1, 2].
May Support Survival Signalling
Across many pre‑clinical models, urolithin A was able to dampen pro‑survival pathways of cancer cells —including PI3K/AKT and Wnt/β‑catenin — and helps stabilize the tumor-suppressor protein p53 [1, 2].
Turning down these “stay‑alive” signals makes cancer cells more vulnerable to stress and therapy.
What Exactly Did the Two Reviews Look At?
We referenced two main articles on the benefit & side effect of urolithin A on cancer. Here's a closer look at how the researchers investigated and the types of cancer cells they covered:
|
Study & Year |
How They Searched |
Cancer Cells Covered |
|
Rogovskii 2022 (Curr Cancer Drug Targets) |
Narrative review of pre‑clinical papers published up to 2021 |
Pancreatic, colon, prostate, breast, lung, glioma |
|
Al‑Harbi 2021 (Frontiers in Nutrition) |
Systematic scan of PubMed & Web of Science to map all urolithin studies |
Breast, prostate, colorectal, bladder, liver, endometrial + more |
Urolithin A and Cancer: Why Does This Matter?
Scientists keep seeing the same pattern when they test urolithin A in lab dishes and in mice: Urolithin A seems to slow cancer-cell growth, shut off their survival switches, and help clean up damaged parts inside the cells.
Getting the same result over and over is a good indicator that Urolithin A might be doing something real.
There's still a big leap from the lab to real-life scenarios. Cells in a Petri dish and mice in a cage live in tightly controlled conditions.
Human bodies are messy and not all the same — we break down urolithin A in different ways and take other medicines, not to mention that each person’s gut bacteria are unique. Because of these variables, urolithin A might not act the same once it’s inside people.
By law, companies are not allowed to say it treats, cures, or prevents any disease — including cancer. That will stay true until good human studies prove otherwise.
Resources:
-
Rogovskii, V. S. (2022). The therapeutic potential of urolithin A for cancer treatment and prevention. Current cancer drug targets, 22(9), 717-724.
-
Al-Harbi, S. A., Abdulrahman, A. O., Zamzami, M. A., & Khan, M. I. (2021). Urolithins: The gut based polyphenol metabolites of ellagitannins in cancer prevention, a review. Frontiers in nutrition, 8, 647582.
